Management of Oral Lichen Planus in Psoriatic Arthritis Patients on DMARDs
Continue the DMARD therapy for psoriatic arthritis while treating the oral lichen planus with topical corticosteroids as first-line therapy; if the OLP is refractory, consider switching to a JAK inhibitor (particularly upadacitinib) or an IL-23 inhibitor (such as risankizumab or guselkumab) which can effectively treat both conditions simultaneously.
Treatment Algorithm
Step 1: Initial OLP Management While Maintaining PsA Control
- Start with topical corticosteroids (clobetasol gel) or topical calcineurin inhibitors for the oral lesions 1
- Continue current DMARD therapy for psoriatic arthritis per EULAR 2023 guidelines 2
- Monitor for candidiasis, which commonly complicates OLP treatment
Step 2: Assess Current DMARD and Consider Drug-Induced OLP
Critical caveat: If the patient is currently on an IL-17 inhibitor (secukinumab, ixekizumab, or bimekizumab), this may be causing or worsening the OLP 3. IL-17 inhibition alters the oral mycobiome, promoting Candida and Aspergillus proliferation, which can trigger or exacerbate OLP.
- If on IL-17 inhibitor: Switch to an IL-23p19 inhibitor (risankizumab or guselkumab), which effectively treats PsA without affecting the oral mycobiome and can dramatically improve OLP within 4 weeks 3
- IL-23 inhibitors are approved for PsA per EULAR guidelines 2
Step 3: For Refractory OLP Despite Topical Therapy
If OLP remains symptomatic after 4-6 weeks of topical therapy:
Option A - JAK Inhibitor (Preferred for dual benefit):
- Upadacitinib 15-30 mg daily is highly effective for both erosive OLP and PsA 4, 5
- JAK1 and JAK3 are overexpressed in lichen planus inflammatory infiltrates, making JAK inhibition mechanistically sound 4
- This addresses both conditions with a single agent
- Per EULAR guidelines, JAKi is appropriate after inadequate response to bDMARD or when bDMARD is not appropriate, though safety considerations must be weighed 2, 6
Option B - Switch to IL-23p19 Inhibitor:
- Risankizumab or guselkumab for PsA (per EULAR recommendations) 2
- These agents do not disrupt oral mycobiome and may improve OLP 3
Step 4: Adjunctive OLP-Specific Measures
- Intralesional triamcinolone for localized erosive lesions 4
- Chlorhexidine rinses for oral hygiene
- Antifungal therapy (miconazole) if candidiasis develops 3
- Avoid hot, spicy foods that exacerbate symptoms 7
Evidence-Based Rationale
The EULAR 2023 guidelines provide a clear treatment hierarchy for PsA: csDMARDs first (methotrexate preferred with skin involvement), then bDMARDs (TNFi, IL-17i, IL-23i), then JAKi for inadequate bDMARD response 2. The choice should account for non-musculoskeletal manifestations and safety considerations regarding individual modes of action 2.
The convergence of recent case reports demonstrates that JAK inhibitors uniquely address both conditions: upadacitinib resolved refractory erosive OLP in patients with PsA where multiple prior therapies failed 4, 5. This represents the highest quality, most recent evidence for dual management.
Critical Pitfalls to Avoid
- Do not continue IL-17 inhibitors if OLP develops or worsens during treatment - this is likely drug-induced 3
- Do not treat OLP and PsA as separate entities - select DMARDs that benefit both conditions
- Do not delay switching therapy if topical OLP treatment fails after 4-6 weeks
- Monitor for candidiasis closely, especially with IL-17 inhibitors or corticosteroid use 3
- Consider diabetes and metabolic comorbidities which can worsen OLP severity and treatment resistance 7
Long-term Monitoring
- Regular oral examinations for malignant transformation risk (though low)
- Assess for sustained remission - approximately 9% of PsA patients achieve true DMARD-free remission, though this is unlikely in patients requiring biologic therapy 8
- Continue interdisciplinary care between rheumatology and oral medicine/dermatology 7